Genovis AB (publ.) Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Genovis AB (publ.) de 13.6% y 19.7% por año respectivamente. Se prevé que el BPA crezca en un 19.9% al año. Se espera que la rentabilidad financiera sea de 18% en 3 años.

Información clave

28.8%

Tasa de crecimiento de los beneficios

31.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	48.6%
Tasa de crecimiento de los ingresos	15.5%
Rentabilidad financiera futura	14.5%
Cobertura de analistas	Low
Última actualización	22 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts

Aug 23

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Apr 26

Recent updates

Genovis AB (publ.)'s (STO:GENO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Sep 19

Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings

Aug 28

Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts

Aug 23

The Genovis AB (publ.) (STO:GENO) Analysts Have Been Trimming Their Sales Forecasts

Aug 21

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Apr 26

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Mar 18

What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash

Feb 28

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Feb 22

These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts

Feb 20

Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be

Feb 04

Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors

Oct 06

Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?

Jun 22

What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?

May 13

Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?

Dec 22

Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?

Nov 14

If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity

Jul 08

Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?

Jun 01

Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%

May 10

One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically

Feb 10

Is Now The Time To Put Genovis AB (publ.) (STO:GENO) On Your Watchlist?

Aug 09

What Is Genovis AB (publ.)'s (STO:GENO) Share Price Doing?

Mar 27

Previsiones de crecimiento de beneficios e ingresos

OM:GENO - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	183	39	36	50	3
12/31/2025	152	35	28	33	3
12/31/2024	129	28	27	50	3
6/30/2024	128	17	27	37	N/A
3/31/2024	128	31	27	39	N/A
12/31/2023	159	62	55	68	N/A
9/30/2023	158	54	40	53	N/A
6/30/2023	151	57	40	49	N/A
3/31/2023	142	42	42	47	N/A
12/31/2022	104	11	-5	-1	N/A
9/30/2022	119	41	40	43	N/A
6/30/2022	112	36	40	43	N/A
3/31/2022	111	36	37	41	N/A
12/31/2021	94	25	41	46	N/A
9/30/2021	71	11	3	6	N/A
6/30/2021	69	12	1	7	N/A
3/31/2021	65	9	-12	9	N/A
12/31/2020	61	6	-17	4	N/A
9/30/2020	54	-3	-16	7	N/A
6/30/2020	64	3	-11	9	N/A
3/31/2020	60	6	4	9	N/A
12/31/2019	61	10	8	13	N/A
9/30/2019	58	12	7	10	N/A
6/30/2019	43	5	0	4	N/A
3/31/2019	40	1	2	3	N/A
12/31/2018	35	-2	-3	-1	N/A
9/30/2018	31	-4	-4	-2	N/A
6/30/2018	27	-6	-6	-5	N/A
3/31/2018	24	-7	N/A	-9	N/A
12/31/2017	23	-8	N/A	-8	N/A
9/30/2017	21	-9	N/A	-9	N/A
6/30/2017	21	-9	N/A	-11	N/A
3/31/2017	20	-14	N/A	-15	N/A
12/31/2016	19	-15	N/A	-16	N/A
9/30/2016	17	-16	N/A	-18	N/A
6/30/2016	16	-21	N/A	-18	N/A
3/31/2016	14	-18	N/A	-14	N/A
12/31/2015	14	-20	N/A	-16	N/A
9/30/2015	13	-25	N/A	-18	N/A
6/30/2015	11	-24	N/A	-20	N/A
3/31/2015	10	-23	N/A	-21	N/A
12/31/2014	10	-22	N/A	-22	N/A
9/30/2014	8	-20	N/A	-18	N/A
6/30/2014	10	-17	N/A	-17	N/A
3/31/2014	11	-16	N/A	-14	N/A
12/31/2013	10	-16	N/A	-12	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (13.6% al año) de GENO es superior a la tasa de ahorro (1%).

Beneficios vs. Mercado: Se prevé que los beneficios (31.2% al año) de GENO crezcan más rápidamente que el mercado Swedish (16.1% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de GENO crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (19.7% al año) de GENO crezcan más rápidamente que los del mercado Swedish (1.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 15.6% al año) de GENO crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de GENO sea baja dentro de 3 años (18%).

Genovis AB (publ.) Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 17% to kr43.00

Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts

Consensus revenue estimates decrease by 13%

Consensus EPS estimates increase by 17%, revenue downgraded

Consensus revenue estimates fall by 11%

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Recent updates

Genovis AB Launches Fabricator® Xtra

Genovis AB (publ.)'s (STO:GENO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Leinco Technologies, Inc. acquired QED Bioscience Inc from Genovis AB (publ.) (OM:GENO).

Leinco Technologies, Inc. acquired QED Bioscience Inc from Genovis AB (publ.) (OM:GENO).

Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings

President & CEO recently bought kr311k worth of stock

Price target decreased by 17% to kr43.00

Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

The Genovis AB (publ.) (STO:GENO) Analysts Have Been Trimming Their Sales Forecasts

Consensus revenue estimates decrease by 13%

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Consensus EPS estimates increase by 17%, revenue downgraded

Investor sentiment deteriorates as stock falls 18%

Genovis AB (publ.)'s (STO:GENO) 36% Jump Shows Its Popularity With Investors

Consensus revenue estimates fall by 11%

This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 19%

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Investor sentiment deteriorates as stock falls 17%

Price target decreased by 16% to kr61.50

Group Chief Financial Officer recently bought kr130k worth of stock

What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Price target decreased by 7.5% to kr68.00

These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts

Genovis AB (publ.) to Report Fiscal Year 2023 Final Results on Apr 24, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 35%

Genovis AB (publ.), Annual General Meeting, May 15, 2024

New major risk - Revenue and earnings growth

Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be

Price target decreased by 8.5% to kr73.50

Consensus revenue estimates fall by 13%

New major risk - Earnings quality

Third quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

Genovis AB (publ.) to Report First Half, 2024 Results on Aug 20, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 15%

Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors

Genovis AB (publ.) to Report Q1, 2024 Results on May 15, 2024

Consensus EPS estimates increase by 22%

Director recently sold kr27m worth of stock

New major risk - Earnings quality

Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?

Genovis Launch Innovative Igm-Specific Protease with Wide-Ranging Applications in Life Science Markets

Consensus EPS estimates increase by 21%

What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Chairman of the Board recently bought kr308k worth of stock

Independent Chairman of the Board recently bought kr308k worth of stock

Vice President of Sales & Marketing recently bought kr89k worth of stock

President & CEO recently bought kr118k worth of stock

Consensus EPS estimates increase by 11%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 8.6% to kr76.00

Genovis AB (publ.) to Report Fiscal Year 2023 Results on Feb 15, 2024

Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?

Price target decreased to kr60.00

Third quarter 2022 earnings released: EPS: kr0.087 (vs kr0.013 in 3Q 2021)

Consensus forecasts updated

Genovis AB (publ.) to Report Nine Months, 2023 Results on Nov 15, 2023

Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?

Genovis AB (publ.) to Report Q1, 2023 Results on May 16, 2023

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity